InvestorsHub Logo
Followers 10
Posts 997
Boards Moderated 0
Alias Born 01/17/2005

Re: None

Thursday, 10/26/2017 1:22:40 PM

Thursday, October 26, 2017 1:22:40 PM

Post# of 2794
Dr. Mark Berger, Actinium's Chief Medical Officer said, "I am delighted to be working with these world-renowned investigators and institutions in this important SIERRA trial for Iomab-B. Their interest and enthusiasm for Iomab-B further motivates my team as we work on this trial to bring Iomab-B to patients who could benefit from safer myeloablation prior to a bone marrow transplant.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ATNM News